Ms. Emily Tan is the COO of Sequencio Therapeutics. She is responsible for Sequencio global business operations and advancing clinical translation of the oncology vaccine pipeline. Ms. Tan has thirty years of experience in the biopharmaceutical field spanning MNCs, CROs and biotech startups. She possesses deep expertise in clinical development and operations management, quality control and regulatory enforcement, and business strategy.

Ms. Tan has held former C suite roles at China biotech companies in Cell and Gene Therapy, where she successfully built operations and led submissions for China-US IND and China IIT. Ms Tan holds an honors bachelor's degree in pharmacy from the National University of Singapore and a master's degree in epidemiology from the London School of Hygiene & Tropical Medicine.

Sequencio Therapeutics is focussed on developing next generation therapeutic cancer vaccines that harness the body's immune system to achieve durable remission. Sequencio has advanced RNA-LNP and protein-based cancer vaccine platforms, powered by an AI-assisted epitope design engine to design vaccines with enhanced immunogenicity. Through epitope driven antigen design, and clinical combination strategies, Sequencio Therapeutics aims to improve durability of anti-cancer efficacy and commercial viability of cancer vaccines.